Braveheart Bio Presents HCM Therapeutic Data at AHA Scientific Sessions
What happened
Carlos del Rio presented research at the American Heart Association Scientific Sessions 2026. The presentations included 52-week extension results for BHB-1893 in obstructive hypertrophic cardiomyopathy and an oral abstract on the drug's ability to improve diastolic function in non-obstructive hypertrophic cardiomyopathy. The presentations were announced by Braveheart Bio, Inc. in October 2026.
From manilatimes.net
Why it matters
The presentation of clinical trial results for BHB-1893, a next-generation cardiac myosin inhibitor, provides information on the long-term efficacy and safety of the therapeutic. This research is relevant to the field of cardiovascular disease treatment.
The American Heart Association hosted the EPI|Lifestyle Scientific Sessions 2026 in Boston.
From manilatimes.net
Who's involved
- Carlos del RioPresented research findings on cardiac therapeutics at the AHA Scientific Sessions.
- American Heart AssociationHosted the Scientific Sessions where the clinical research data was presented.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- New cardiac myosin inhibitor data may shift Edwards Lifesciences' marketNew cardiac myosin inhibitor data may shift Edwards Lifesciences' marketPossible
- Cleveland Clinic may adjust protocols based on new cardiac dataNew cardiac data may prompt changes to guidelines used by Cleveland ClinicPossible
- New cardiac myosin inhibitor data may influence ACC guidelinesNew cardiac myosin inhibitor data may influence ACC guidelinesPossible
Keep exploring
The entities involved
-
Carlos del Rio
Mexican-American physician
Nothing else this week.
-
American Heart Association
US nonprofit funding cardiovascular medical research, educating consumers on healthy living, and fostering cardiac care